Drug Profile
Fampridine sustained release - Acorda Therapeutics
Alternative Names: 4-AP - Acorda Therapeutics; Ampyra; BIIB 041; Dalfampridine ER; Dalfampridine extended-release; Dalfampridine-SR; EL 970; Fampridine ER; Fampridine extended-release; Fampridine-PR; Fampridine-SR; Fampyra; NeurelanLatest Information Update: 08 Apr 2024
Price :
$50
*
At a glance
- Originator Elan Drug Technologies
- Developer Acorda Therapeutics; Biogen; John Hopkins University; Kessler Foundation; University of California at Los Angeles; University of Florida; University of Miami
- Class Aminopyridines; Neuroprotectants; Small molecules
- Mechanism of Action Potassium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Multiple sclerosis
- Phase III Ataxia
- Phase II Spinal cord injuries; Spinocerebellar degeneration
- Phase I/II Parkinson's disease
- No development reported Cerebral palsy
- Discontinued Neurological disorders; Transverse myelitis
Most Recent Events
- 02 Apr 2024 Merz Pharmaceuticals enters into an asset purchase agreement with Acorda Therapeutics to acquire Inbrija and Amprya
- 11 Jan 2024 Acorda anticipates termination of its licensing agreement with Biogen for fampridine sustained release in Africa, Asia, Australasia, Europe, Far-East, Middle-East in January 2025
- 24 Mar 2022 Biogen plans to launch fampridine sustained release for Multiple sclerosis in China (PO)